Impact of clinical pharmacist’s interventions on clinical outcomes in appropriate use of colistin: a prospective pre-post intervention study

Abstract

This study aims to evaluate the clinical pharmacist’s contribution impact on the appropriate use of colistin. Our study was conducted prospectively in patients in the Internal Diseases Intensive Care Unit of Gazi University Medical Faculty Hospital for eight months. The first four months of the study were with the observation group, while the next four months were with the intervention group. The study determined how the active participation of clinical pharmacists had affected the appropriateness of colistin use. The results showed that the appropriate use of colistin was higher in the intervention group than in the observational group; furthermore, incidence of nephrotoxicity was lower. The difference between both groups was statistically significant (p < 0.001, p < 0.05), respectively. This study showed that the clinical pharmacist’s active intervention by following the patients increased the frequency and percentage of the appropriate use of colistin. This decreased the incidence of nephrotoxicity, colistin’s most important side effect.

Keywords:

• Colistin
• clinical pharmacist
• appropriate use
• intensive care unit
• nephrotoxicity
• critical care

Acknowledgements

We would like to thank both article reviewers for their valuable suggestions.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethics approval and consent to participate

This study was approved by the Gazi University Faculty of Medicine Clinical Research Ethics Committee, Ankara/Turkey, and was conducted according to the Declaration of Helsinki and Good Clinical Practice (GCP) (No:160/10.02.2020). Permission was obtained from the Turkish Medicines and Medical Devices Agency (No:E-66175679-514.05.01-49629/25.02.2020).

Patient consent for publication

Obtained.

Additional information

Funding

The authors received no specific funding for this work.